China's Hansoh Pharmaceutical Group beats net profit expectations in 2025

Reuters03-29

China's Hansoh Pharmaceutical Group beats net profit expectations in 2025

SHANGHAI, March 29 (Reuters) - China's Hansoh Pharmaceutical Group 3692.HK, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.

The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.

Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan ($804.44 million), well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG.

Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.

In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.

The deal was a part of a string of new licensing agreements last year with other overseas drugmakers including the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS and Regeneron Pharmaceuticals REGN.NO.

($1 = 6.9116 Chinese yuan renminbi)

(Reporting by Andrew Silver and Ju-min Park, editing by Susan Fenton)

((andrew.silver@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623356495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623356495","market":"us","top_or_hot":-1,"title":"China's Hansoh Pharmaceutical Group beats net profit expectations in 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>China's Hansoh Pharmaceutical Group beats net profit expectations in 2025</title></head><body><p><span>SHANGHAI, March 29 (Reuters)</span><span> - </span>China's Hansoh Pharmaceutical Group <span>3692.HK</span>, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.</p><p>The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.</p><p>Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan ($804.44 million), well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG. </p><p>Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.</p><p>In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>The deal was a part of a string of new licensing agreements last year with other overseas drugmakers including the Swiss arm of India's Glenmark Pharmaceuticals <span>GLEN.NS</span> and Regeneron Pharmaceuticals <span>REGN.NO</span>. </p><p>($1 = 6.9116 Chinese yuan renminbi)</p><p> (Reporting by Andrew Silver and Ju-min Park, editing by Susan Fenton)</p><p> ((andrew.silver@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Hansoh Pharmaceutical Group beats net profit expectations in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Hansoh Pharmaceutical Group beats net profit expectations in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>China's Hansoh Pharmaceutical Group beats net profit expectations in 2025</title></head><body><p><span>SHANGHAI, March 29 (Reuters)</span><span> - </span>China's Hansoh Pharmaceutical Group <span>3692.HK</span>, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.</p><p>The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.</p><p>Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan ($804.44 million), well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG. </p><p>Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.</p><p>In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche <span>ROG.S</span> for an investigational treatment of colorectal cancer and other solid tumours.</p><p>The deal was a part of a string of new licensing agreements last year with other overseas drugmakers including the Swiss arm of India's Glenmark Pharmaceuticals <span>GLEN.NS</span> and Regeneron Pharmaceuticals <span>REGN.NO</span>. </p><p>($1 = 6.9116 Chinese yuan renminbi)</p><p> (Reporting by Andrew Silver and Ju-min Park, editing by Susan Fenton)</p><p> ((andrew.silver@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823434583.USD","symbol_name":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260329:nL6N3ZY0K1:1","article_id":"2623356495","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623356495","pubTimestamp":1774786084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China's Hansoh Pharmaceutical Group beats net profit expectations in 2025SHANGHAI, March 29  - China's Hansoh Pharmaceutical Group 3692.HK, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan , well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG. Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0058720904.USD":"联博国际健康护理基金A","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK1589":"北水核心资产","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK1191":"制药","REGN":"再生元制药公司","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","03692":"翰森制药","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4585":"ETF&股票定投概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK1583":"高瓴概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"中国翰森制药集团2025年净利润超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"REGN":0.9},"content_text":"China's Hansoh Pharmaceutical Group beats net profit expectations in 2025SHANGHAI, March 29 (Reuters) - China's Hansoh Pharmaceutical Group 3692.HK, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan ($804.44 million), well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG. Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche ROG.S for an investigational treatment of colorectal cancer and other solid tumours.The deal was a part of a string of new licensing agreements last year with other overseas drugmakers including the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS and Regeneron Pharmaceuticals REGN.NO. ($1 = 6.9116 Chinese yuan renminbi) (Reporting by Andrew Silver and Ju-min Park, editing by Susan Fenton) ((andrew.silver@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623356495","isCrawlerRequest":true}